Biosimilar Policy Update: Extrapolation Looks Like Default Approach
This article was originally published in RPM Report
Executive Summary
As FDA nears the first review deadlines for biosimilar applications, some policy points are coming into sharper focus. Clinical studies for immunogenicity sound like a benchmark requirement, while extrapolation of indications also seems like the agency’s default position.
You may also be interested in...
Will 2016 Be The Year of the Biosimilar?
The first wave of biosimilars seemed ready to come to market in 2015, but only one product actually made it through FDA. The coming year might be the year when multiple biosimilars enter the US.
Will 2016 Be The Year of the Biosimilar?
The first wave of biosimilars seemed ready to come to market in 2015, but only one product actually made it through FDA. The coming year might be the year when multiple biosimilars enter the US.
Words Of Wisdom For Biosimilar Developers
FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.